Pacific Biosciences of California, Inc. (PACB) Earnings History
Net Loss18 years of earnings data (2008–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Pacific Biosciences of California, Inc. (PACB) Earnings Overview
As of June 22, 2026, Pacific Biosciences of California, Inc. (PACB) reported trailing twelve-month net income of -$129M, reflecting -70.1% year-over-year growth. The company earned $-0.42 per diluted share over the past four quarters, with a net profit margin of -341.5%.
Looking at the long-term picture, PACB's historical earnings data spans multiple years. The company achieved its highest annual net income of $29M in fiscal 2020.
Pacific Biosciences of California, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ILMN ($853M net income, 19.6% margin), BFLY (-$76M net income, -79.0% margin), CDNA (-$8M net income, -5.6% margin), PACB has room to improve margins relative to the peer group. Compare PACB vs ILMN →
PACB Earnings vs Peers
Earnings metrics vs comparable public companies
PACB Historical Earnings Data (2008–2025)
18 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$546M | -76.3% | -$558M | $-1.82 | -341.5% | -348.5% |
| 2024 | -$310M | -1.0% | -$474M | $-1.07 | -201.2% | -308.0% |
| 2023 | -$307M | +2.4% | -$334M | $-1.21 | -153.0% | -166.8% |
| 2022 | -$314M | -73.4% | -$307M | $-1.40 | -244.9% | -239.4% |
| 2021 | -$181M | -716.3% | -$210M | $-0.89 | -138.9% | -161.2% |
| 2020 | $29M | +134.9% | -$104M | $0.17 | 37.3% | -132.3% |
| 2019 | -$84M | +18.0% | -$101M | $-0.51 | -92.6% | -110.6% |
| 2018 | -$103M | -11.3% | -$101M | $-0.76 | -130.4% | -128.4% |
| 2017 | -$92M | -24.0% | -$90M | $-0.87 | -98.6% | -96.1% |
| 2016 | -$74M | -134.7% | -$71M | $-0.83 | -82.0% | -78.5% |
| 2015 | -$32M | +52.1% | -$29M | $-0.42 | -34.2% | -31.4% |
| 2014 | -$66M | +16.6% | -$63M | $-0.94 | -109.2% | -103.7% |
| 2013 | -$79M | +16.1% | -$78M | $-1.26 | -281.4% | -275.2% |
| 2012 | -$94M | +13.6% | -$94M | $-1.69 | -363.6% | -363.1% |
| 2011 | -$109M | +22.0% | -$110M | $-2.03 | -323.0% | -324.1% |
| 2010 | -$140M | -59.8% | -$140M | $-5.21 | -8373.1% | -8377.2% |
| 2009 | -$88M | -100.4% | -$88M | $-113.33 | -64965.2% | -65237.0% |
| 2008 | -$44M | - | -$45M | $-56.54 | -4856.2% | -4973.3% |
Download Data
Export PACB earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
18+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PACB — Frequently Asked Questions
Quick answers to the most common questions about buying PACB stock.
What is PACB earnings per share (EPS)?
PACB trailing twelve-month (TTM) diluted EPS is $-0.42, reflecting -70.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2008 to 2025 is available in the table on this page.
What is Pacific Biosciences of California, Inc.'s net income?
Pacific Biosciences of California, Inc. (PACB) trailing twelve-month net income is $-129M as of 2025. Earnings declined -70.1% year-over-year.
Is PACB profitable?
PACB is not currently profitable on a TTM basis, reporting a net loss of $-129M. Net margin is -341.5%. Investors should monitor for a return to profitability.
What is PACB's earnings growth rate?
PACB compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2008 to 2025.
What are PACB's profit margins?
Pacific Biosciences of California, Inc. net profit margin is -341.5%, operating margin is -348.5%, and gross margin is +31.7%. Below-average margins reflect competitive or cost pressures. Return on Equity is -213.5%.
Is PACB growing earnings?
PACB earnings are declining — EPS fell -70.1% year-over-year. TTM net income dropped to $-129M. This contrasts with the 5-year CAGR of N/A.
What was PACB's best earnings year?
Pacific Biosciences of California, Inc.'s highest annual net income on record is $29M, achieved in fiscal year 2020. Earnings history on this page spans 2008 to 2025 and includes all annual and quarterly figures.
What were PACB's earnings last quarter?
PACB's most recent reported quarter was Q1 2026. Net income was $-8M with diluted EPS of $-0.03. For a full breakdown of all quarters, see the quarterly earnings table on this page.